R

Roche

Global pharmaceuticals and diagnostics company

Technical Product Owner - Digital Workplace Productivity Engineering Team

Full-TimeDeadline 10/27/26
No salary listed
Mid
Madrid, Spain
Hybrid
ProductProduct Management

About the job

Requirements
  • Professional proficiency in English, with strong oral and written communication skills.
  • Deep knowledge of the Microsoft 365 ecosystem and architecture, particularly its productivity, communication and collaboration capabilities and their dependencies.
  • Strong hands-on technical experience with Microsoft Teams and enterprise collaboration technologies, including collaboration, meetings, communication, policies and integrated productivity scenarios.
  • Strong understanding of enterprise messaging, Outlook and calendaring concepts and their role within the broader employee productivity experience.
  • Good understanding of the broader Microsoft 365 ecosystem, including collaboration, content, identity, permissions, information access, security and service dependencies.
  • Experience as a Product Owner, Technical Product Owner or equivalent role, ideally for enterprise technology products, platforms or capabilities.
  • Practical experience with Product Ownership and Agile delivery, including backlog ownership, prioritization, roadmap alignment, requirements refinement, user stories and acceptance criteria.
  • Proven ability to translate complex employee, business and technology needs into clear product requirements, priorities and actionable engineering outcomes.
  • Understanding of security, privacy, compliance and information-governance principles and how they influence enterprise productivity and AI-enabled solutions.
  • Strong analytical and troubleshooting capabilities, including the ability to understand complex cross-service technical and architectural dependencies and contribute effectively to complex issues and escalations.
  • Understanding of Microsoft 365 service lifecycle management, including roadmap evaluation, technical impact assessment, testing, pilots and enterprise adoption.
  • Strong understanding of AI-enabled productivity, particularly Microsoft 365 Copilot, including how enterprise information, identity, permissions, security, privacy and governance influence AI experiences.
  • A strong Product Owner mindset and deep technical expertise, with comfort moving between product direction, stakeholder discussions, prioritization, architecture and technical problem solving.
  • Ability to take accountability for product priorities and decisions and make effective trade-offs across employee value, business needs, technology, risk and delivery constraints.
  • Ability to translate strategy, employee needs and technology opportunities into clear and executable engineering work while maintaining focus on product value and outcomes.
  • An employee-experience and productivity mindset, with the ability to consider how technology can make employees more effective.
  • Technical credibility to challenge assumptions, evaluate proposed solutions and understand their implications while partnering effectively with architects and engineering teams.
  • Ability to think end-to-end and recognize that productivity experiences span multiple technologies, products, services and organizational boundaries.
  • Passion for Artificial Intelligence and its potential to transform the digital workplace, with the ability to identify meaningful enterprise use cases.
  • Ability to navigate complexity and ambiguity as Microsoft 365, AI and modern workplace technologies evolve.
  • Ability to collaborate across teams and influence and create alignment in a global and multicultural environment.
Responsibilities
  • Take end-to-end Product Ownership responsibility for assigned Digital Workplace Productivity capabilities, defining priorities and desired outcomes in alignment with the broader Digital Workplace strategy.
  • Own, prioritize and continuously refine the product backlog, ensuring alignment with product strategy, roadmap, employee value, technical needs, dependencies, risks and engineering capacity.
  • Translate employee needs, business requirements and technology opportunities into clear epics, features and actionable user stories, with well-defined outcomes and acceptance criteria.
  • Shape product priorities and roadmap with stakeholders, architects, engineers and partner teams, making informed trade-offs across value, technical feasibility, architecture, dependencies, risk and delivery effort.
  • Apply Microsoft 365 technical expertise to guide product and solution decisions, challenge assumptions, understand architectural implications and help ensure solutions are scalable, secure and sustainable.
  • Guide the evolution of Microsoft Teams and related Microsoft 365 productivity capabilities across collaboration, communication, meetings, email, calendaring and integrated employee experiences.
  • Maintain a deep understanding of the broader Microsoft 365 architecture, components and service dependencies, collaborating across organizational and technology boundaries to address complex cross-service scenarios.
  • Evaluate Microsoft 365 roadmap changes and emerging technologies through technical impact assessments, proofs of concept, testing and pilots, supporting controlled and sustainable enterprise adoption.
  • Explore and evaluate AI-enabled productivity solutions, including Microsoft 365 Copilot and emerging AI capabilities, identifying valuable use cases while considering information access, identity, permissions, security, privacy, governance and responsible use of AI.
  • Identify opportunities to combine collaboration, automation and AI to simplify employee workflows, reduce repetitive activities and improve access to information.
  • Define and evaluate product outcomes and success measures, using employee feedback, adoption, usage and service insights to continuously improve product value, service quality and employee experience.
  • Maintain visibility of priorities, progress, dependencies and risks, collaborating across product, engineering and service teams and contributing technical expertise to solution validation, troubleshooting and complex incidents or technical challenges when needed.
Desired Qualifications
  • Experience with automation or scripting technologies.
  • Experience with AI technologies, intelligent workplace solutions or conversational experiences.
  • Relevant Microsoft certifications and demonstrated hands-on experience with Microsoft 365 technologies.
  • Significant experience with Microsoft 365 technologies in a large-scale enterprise environment.
  • Experience acting as a Product Owner, Technical Product Owner or equivalent for enterprise technology products or capabilities.
  • Experience working at the intersection of product ownership and engineering, combining product accountability with strong technical expertise.
  • Experience designing or evolving solutions that improve digital collaboration and employee productivity.
  • Experience working in complex environments with dependencies across multiple technologies, products, engineering teams and service owners.
  • Experience evaluating and introducing new cloud or AI-enabled productivity capabilities through structured assessment, experimentation and adoption.

About the company

Roche is a global leader in pharmaceuticals and diagnostics. It develops medicines and diagnostic tools that help detect, monitor, and treat diseases, using research and biotechnology to drive new therapies and tests. Roche combines drug development with in-house diagnostic products to support personalized medicine, where treatments are tailored to individual patients based on test results. Its approach differs from many peers by integrating drug discovery with diagnostic capabilities and by expanding its research through strategic acquisitions (like Genentech) to strengthen its biotechnology and R&D capabilities. The company’s goal is to improve patient outcomes and healthcare worldwide by delivering reliable medicines, accurate diagnostic tests, and data-driven care.

Company Size

1-10

Company Stage

IPO

Headquarters

Basel, Switzerland

Founded

1896

Get referred to Roche

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Enicepatide delivered 15.5% weight loss in September 2026 and 22.7% in June.
  • pTau217 can scale immediately through Roche's existing lab network and improve Alzheimer diagnostics.
  • Roche's June 2026 data and September 2026 filings signal multiple obesity shots on goal.

What critics are saying

  • Eli Lilly and Novo Nordisk dominate obesity pricing, distribution, and physician mindshare today.
  • Enicepatide remains Phase II-only; Roche starts late-stage glycemic and cardiovascular studies in 2027.
  • If enicepatide disappoints, Roche burns its $2.7 billion Carmot bet and loses obesity credibility.

What makes Roche unique

  • Roche combines pharma, diagnostics, and installed cobas labs across 4,500 U.S. instruments.
  • Elecsys pTau217 won FDA clearance on August 24, 2026, and CE marking September 7.
  • Roche controls obesity assets from Carmot and Zealand, spanning GLP-1/GIP and amylin.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Performance Bonus

Company News

Yahoo Finance
Oct 22nd, 2026
Roche reaffirms outlook as Q3 sales rise 7% to $19.6B, but growth doubts linger

Roche reaffirmed its 2025 outlook on Thursday and beat third-quarter sales expectations, but questions about its long-term growth remain. Group sales rose 7% to 16.1 billion Swiss francs (about $19.6 billion), ahead of the 15.8 billion franc consensus estimate. Jefferies analyst Michael Leuchten said a new resource planning system boosted revenue, making the results "cosmetically ahead." Roche still expects group sales growth in the "mid single digit range" and did not raise guidance. Sales of allergy and asthma drug Xolair reached only 848 million francs, well below estimates. A copycat version launched in the US this month, and Ocrevus and Tecentriq face generic competition by 2030. Roche is counting on its breast cancer pill giredestrant, which awaits a US Food and Drug Administration decision by December 18, and on obesity drugs. It says the products could together reach $9 billion in peak annual sales.

CNBC
Oct 22nd, 2026
Roche CEO presses Germany on growth strategy as drugmaker pauses investment there

Roche chief executive officer Thomas Schinecker has challenged Germany over its growth strategy, saying pharmaceutical firms are "the industry they need to bet on." Schinecker discussed the company's third-quarter earnings and its recent expansion in China. He also outlined recent pharmaceutical developments at the business. He explained why Roche has paused investment in Germany.

Yahoo Finance
Oct 16th, 2026
FDA approves Roche's Enspryng as first at-home injection for thyroid eye disease

Roche said the US Food and Drug Administration (FDA) has approved Enspryng (satralizumab) for adults with thyroid eye disease (TED). It is the first and only at-home subcutaneous treatment for the condition, and a patient or caregiver can administer it after training. In the Phase III SatraGO-2 trial, 52.9% of active TED patients on Enspryng had a proptosis (eye bulging) response, against 23.4% on placebo. Double vision fell in 60.7% of patients, against 25.8%. The SatraGO-1 trial missed its primary endpoint at Week 24. No new safety signals emerged. TED affects about 155 in every 100,000 people in the US. This is Enspryng's second approval, after neuromyelitis optica spectrum disorder in 2020. The FDA is also reviewing it for myelin oligodendrocyte glycoprotein antibody-associated disease, with a decision expected in January 2027.

Yahoo Finance
Oct 9th, 2026
FDA approves Roche's Tecentriq for stage III colon cancer, cutting recurrence risk by 50%

The US Food and Drug Administration has approved Roche's Tecentriq in combination with a fluoropyrimidine and oxaliplatin for adjuvant treatment of stage III deficient DNA mismatch repair colon cancer. This marks Tecentriq's twelfth approved indication in the US. The approval follows the phase III ATOMIC study, published in The New England Journal of Medicine, which demonstrated that Tecentriq plus chemotherapy reduced the risk of disease recurrence or death by 50% compared to chemotherapy alone. The 36-month disease-free survival rate was 86% with the combination versus 76% with chemotherapy alone. Nearly 25% of colon cancers are diagnosed at stage III, and almost one in three stage III patients experience recurrence within five years. This represents the first approved adjuvant immunotherapy regimen for this patient population. Roche is pursuing further regulatory filings, including with the European Medicines Agency.

Yahoo Finance
Sep 30th, 2026
Roche's enicepatide shows 22.5% weight loss in 48 weeks, challenging Eli Lilly and Novo Nordisk

Roche posted strong Phase 2 results for its weight loss drug enicepatide, showing 22.5% mean weight loss over 48 weeks. This compares favourably to Eli Lilly's Zepbound, which achieved 20.2% weight loss over 72 weeks in a separate trial. In another Phase 2 study, enicepatide demonstrated HbA1c reductions of up to 2.65 percentage points in diabetic patients after 48 weeks, compared to tirzepatide's 2.37 percentage points after 52 weeks. Despite promising results, Roche faces stiff competition from Novo Nordisk and Eli Lilly, which both have deep pipelines in development. Novo Nordisk's CagriSema is nearing approval, whilst Eli Lilly's retatrutide has posted strong Phase 3 results. Roche's revenue grew 6% year over year in the first half of the year to 30.4 billion Swiss francs.